Jeffrey James Roix

Opal Oncology Ltd. operates as a pharmaceutical company. It develops drugs for cancer. The company was founded in 2012 and is headquartered in Cambridge, the United Kingdom.

O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom.

Stingray Bio Ltd. is a British biotechnology research company founded in 2020. The company is based in Brighton, UK. The company provides research services in the field of biotechnology.

Opal Oncology Ltd. operates as a pharmaceutical company. It develops drugs for cancer. The company was founded in 2012 and is headquartered in Cambridge, the United Kingdom.

O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom.

PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom.

PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom.

PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom.